Articles written by NanoViricides - Benzinga

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides

Shelton, Connecticut -- August 21, 2023 -- NanoViricides, Inc.

Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness In RSV In A Lethal Lung Disease Animal Model, Reports NanoViricides

Shelton, Connecticut -- July 11, 2023 -- NanoViricides, Inc.

Clinical Trial Of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well, Says NanoViricides - NV-CoV-2 Is Positioned To Fulfill Many Unmet Medical Needs

SHELTON, CONNECTICUT - July 6, 2023 - NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.

NanoViricides Signs A License Agreement That Includes Clinical Evaluation Of Its COVID-19 Drug Candidates

Shelton, Connecticut – April 4, 2023 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).

NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials

SHELTON, CONNECTICUT -- Wednesday, February 15, 2023 -- NanoViricides, Inc.

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage

SHELTON, CONNECTICUT -- Friday, October 14, 2022 -- NanoViricides, Inc.

NanoViricides Provides Additional Details On Its Rapid Monkeypox Drug Strategy

SHELTON, CONNECTICUT — August 9, 2022 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus.

NanoViricides Reports That It Has Begun Drug Development To Combat Recent Cases Of Severe Pediatric Hepatitis

SHELTON, CONNECTICUT – May 16, 2022 -- NanoViricides, Inc.

NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.